4DX

0.96%

51.5¢ 4dmedical limited

Ann: Application for quotation of securities - 4DX, page-83

First 83 Last

Share
Profile

Follow
UberTrader

801 Posts.

83

26/07/24

16:38

Post #: 74936286
Share

Originally posted by Frederic0: ↑

Trust that AI ...

-----

In the case of a medical company engaged in extensive research and development (R&D), dilution can indeed be beneficial in the long run, especially if the company is working towards strategic goals with the potential for significant future revenue.

Here are some key points to consider:
1. **Funding R&D**: Medical research is capital-intensive and often requires substantial investment over extended periods. Issuing new shares to fund R&D can ensure the company has the necessary resources to continue its projects without relying heavily on debt, which could be risky.

2. **Pipeline Development**: If the company's research is progressing well and is close to achieving breakthroughs, the additional funding from share issuance can expedite the development process. This can include advancing clinical trials, obtaining regulatory approvals, and scaling up production.

3. **Long-term Value Creation**: Successful R&D in the medical field can lead to the development of new treatments, drugs, or medical devices that can generate significant revenue. If the company achieves its strategic goals, the long-term value created can far outweigh the short-term dilution of shares.

4. **Market Positioning**: A medical company with a strong pipeline of innovative products can enhance its market position, attract strategic partners, and increase its competitive advantage. This can lead to higher market share and sustained revenue growth.

5. **Investor Confidence**: Transparent communication about the progress of research and the strategic use of funds can maintain and even boost investor confidence. Investors may be more willing to accept short-term dilution if they believe in the long-term potential and strategic direction of the company.

6. **Risk Mitigation**: Dilution spreads the financial risk among a larger base of shareholders, reducing the burden on existing investors. This can be particularly important in the high-risk, high-reward environment of medical research.

While the delay in realizing revenue might cause some short-term concerns, the critical factor is the company's potential to achieve its strategic goals and deliver significant long-term returns. If the company demonstrates progress and clear potential for future success, the dilution can be justified as a necessary step towards achieving those objectives.

Expand

All that good but it happens before FDA approval and reimbursement code issued and after that one need to start talking revenue, cost cut and continue towards self sufficient to invest in research and sometimes it is better to sell company to big brother which creates immediate value to shareholders as big brother like Phillips can put much needed cash to advance technology if there is any further future.

4DX Price at posting: 51.5¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

OPL

Opyl forms JV with UK and US consortium to bring products to the world

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

AAI

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

HXL

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

There are more pages in this discussion • 4 more messages in this thread...

First 83 Last

Add 4DX (ASX) to my watchlist

(20min delay)
Last 51.5¢		Change -0.005(0.96%)		Mkt cap ! $211.4M

Open	High	Low	Value	Volume
52.0¢	53.0¢	51.3¢	$172.7K	333.3K

Buyers (Bids)

No.	Vol.	Price($)
2	39195	51.5¢

Sellers (Offers)

Price($)	Vol.	No.
52.5¢	10000	1

View Market Depth

No.	Vol.	Price($)
2	39195	0.515
17	207188	0.510
7	96358	0.505
17	187200	0.500
3	56571	0.495

Price($)	Vol.	No.
0.525	10000	1
0.530	41643	4
0.535	317	1
0.540	7501	1
0.545	11761	2

Last trade - 16.10pm 26/07/2024 (20 minute delay)

4DX (ASX) Chart

Ann: Application for quotation of securities - 4DX, page-83

Opyl forms JV with UK and US consortium to bring products to the world

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Application for quotation of securities - 4DX, page-83

Top Stories

Opyl forms JV with UK and US consortium to bring products to the world

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Geochemical work at Newington picks up gold and copper anomalies for Midas

NYSE-listed Alcoa Corp joins ASX through key JV acquisition

Acquisitions roundup: European Lithium, Diatreme Resources and SRJ Technologies

Quarterly & half yearly reports: Drives Newmont up, Ampol flat, while Fortescue plunges 2.6%

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM

Hexima shares rise 66% on proposed acquisition of AI player Real Thing Entertainment

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News